| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 02/19/2004 | US20040033980 Method of down-regulating gene expression |
| 02/19/2004 | US20040033958 Such as (N-((R,S)-2-(2-(N-methyl)pyrrolidinyl)ethyl)glycyl)-(N-(4 -methoxyphenethyl)glycyl)-N-(3-methylbutyl)glycinamide; for treatment of pain |
| 02/19/2004 | US20040033952 Modified mature insulin variants and composition containing same |
| 02/19/2004 | US20040033951 Modified mature insulin variants and composition containing same |
| 02/19/2004 | US20040033946 Cell damage inhibitor |
| 02/19/2004 | US20040033936 Reduced or "leuco" forms produced and/or stabilised by mixing the unreduced compounds or the reduced compounds, respectively, with acid and a sulphydryl compound, especially a sulphur-containing amino acid, or peptide or derivative |
| 02/19/2004 | US20040033597 Multipotent neural stemcells from peripheral tissues and uses thereof |
| 02/19/2004 | US20040033563 Ho-1 suppressor as a diagnostic and prognostic test for dementing diseases |
| 02/19/2004 | US20040033253 Transdermal-delivery device |
| 02/19/2004 | US20040033252 Containing a branched-chain amino acid such as valine, leucine or isoleucine, or 2-aminonorbornane-2-carboxylic acid |
| 02/19/2004 | US20040033250 Implantable polymeric device for sustained release of buprenorphine |
| 02/19/2004 | US20040033231 First domain comprising a PP14 polypeptide sequence and a second domain comprising a polypeptide sequence of the Fc region of an immunoglobulin protein; treatment of immune system diseases and disorders |
| 02/19/2004 | US20040033202 Nanoparticulate sterol formulations and novel sterol combinations |
| 02/19/2004 | DE10217555A1 Physiologisch verträgliche, Phospholipid-haltige, stabile und harte Matrix Physiologically acceptable, phospholipid-containing, stable and hard matrix |
| 02/19/2004 | CA2840721A1 Method of preparing modafinil polymorphic form i |
| 02/19/2004 | CA2804385A1 Method of preparing modafinil polymorphic form i |
| 02/19/2004 | CA2746788A1 Modafinil polymorphic forms |
| 02/19/2004 | CA2497658A1 Chromone derivatives as matrix metalloproteinase inhibitors |
| 02/19/2004 | CA2495518A1 Bicyclic heteroaromatic compounds as kinase inhibitors |
| 02/19/2004 | CA2495516A1 Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia |
| 02/19/2004 | CA2495502A1 Methods for treating carbonic anhydrase mediated disorders |
| 02/19/2004 | CA2495266A1 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases |
| 02/19/2004 | CA2495179A1 Compounds having an activity at metabotropic glutamate receptors |
| 02/19/2004 | CA2495120A1 Oxadiazoles as modulators of metabotropic glutamate receptor-5 |
| 02/19/2004 | CA2495108A1 Therapeutic use of aryl amino acid derivatives |
| 02/19/2004 | CA2494942A1 Substituted benzimidazole compounds |
| 02/19/2004 | CA2494908A1 Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation |
| 02/19/2004 | CA2494865A1 Electrospun amorphous pharmaceutical compositions |
| 02/19/2004 | CA2494827A1 Cannabinoid receptor ligands |
| 02/19/2004 | CA2494785A1 Dihydropyrazolopyridine compounds |
| 02/19/2004 | CA2494585A1 Methods for the treatment of dementia based on apo e genotype |
| 02/19/2004 | CA2494298A1 Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| 02/19/2004 | CA2494108A1 Amyloid immunization and cox-2 inhibitors for the treatment of alzheimer's disease |
| 02/19/2004 | CA2494028A1 Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors |
| 02/19/2004 | CA2494026A1 Phosphodiesterase 4 inhibitors |
| 02/19/2004 | CA2493660A1 Process for preparing quinolin antibiotic intermediates |
| 02/19/2004 | CA2493625A1 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 02/19/2004 | CA2493575A1 Tyrosine kinase inhibitors |
| 02/19/2004 | CA2493297A1 Methods to reprogram splice site selection in pre-messenger rnas |
| 02/19/2004 | CA2493143A1 2,3-dihydro-isoindol-1-ones with mao-b inhibiting activity |
| 02/18/2004 | EP1389624A1 Phosphorous-containing cysteine and serine protease inhibitors |
| 02/18/2004 | EP1389619A1 Pkb-3564 substance with neovascularization inhibitory activity |
| 02/18/2004 | EP1389618A1 Pyrazolo 1,5-a]pyridines and medicines containing the same |
| 02/18/2004 | EP1389306A2 Method for detecting progredient chronic dementia, and corresponding peptides and detection reagents |
| 02/18/2004 | EP1389237A2 Novel fibroblast growth factors |
| 02/18/2004 | EP1389233A1 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
| 02/18/2004 | EP1389208A1 Substituted azabicyclic moieties for the treatment of disease (nicotinic acethylcholine receptor antagonists) |
| 02/18/2004 | EP1389206A2 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| 02/18/2004 | EP1389201A1 N-oxide anthranylamide derivatives and their use as medicaments |
| 02/18/2004 | EP1389200A1 Substituted n-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors |
| 02/18/2004 | EP1389194A2 Inhibitors of bace |
| 02/18/2004 | EP1389189A2 Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues |
| 02/18/2004 | EP1389183A1 Sulfonamide derivatives |
| 02/18/2004 | EP1389181A2 Antioxidant nitroxides and nitrones as therapeutic agents |
| 02/18/2004 | EP1389130A2 Use of osteopontin for the treatment and/or prevention of neurologic diseases |
| 02/18/2004 | EP1389124A1 Palliative effects of morinda citrifolia oil and juice |
| 02/18/2004 | EP1389121A1 Method and compositions for treating mammalian nerve tissue injuries |
| 02/18/2004 | EP1389119A1 A pharmaceutical composition comprising lysophosphatidic acid |
| 02/18/2004 | EP1389112A2 Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders |
| 02/18/2004 | EP1389110A2 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| 02/18/2004 | EP1389107A1 Bisarylimidazolyl fatty acid amide hydrolase inhibitors |
| 02/18/2004 | EP1389100A2 Novel methods for the treatment and prevention of pain using stress-activated protein kinase inhibitors |
| 02/18/2004 | EP1389099A1 Delivery of beta-blockers through an inhalation route |
| 02/18/2004 | EP1389098A1 Delivery of antipsychotics through an inhalation route |
| 02/18/2004 | EP1389097A1 Delivery of compounds for the treatment of parkinsons through an inhalation route |
| 02/18/2004 | EP1389096A1 Delivery of opioids through an inhalation route |
| 02/18/2004 | EP1389095A1 Delivery of antidepressants through an inhalation route |
| 02/18/2004 | EP1389094A1 Delivery of sedative-hypnotics trough an inhalation route |
| 02/18/2004 | EP1389092A1 Abuse-resistant opioid dosage form |
| 02/18/2004 | EP1389091A1 Granular preparations of gaboxadol |
| 02/18/2004 | EP1292572B1 Propanolaminotetralines, preparation thereof and compositions containing same |
| 02/18/2004 | EP1233786B1 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance for the preparation of a medicament |
| 02/18/2004 | EP1216248B1 Triazolopyrimidine derivatives |
| 02/18/2004 | EP1216238B1 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 02/18/2004 | EP1183252B1 pharmaceutically active compounds |
| 02/18/2004 | EP1178958B1 N-cyanomethyl amides as protease inhibitors |
| 02/18/2004 | EP1171416B1 3-bicycloaryl-2-aminomethyl bicycloalkanes as serotonine reuptake inhibitors |
| 02/18/2004 | EP1133494B1 8-azabicyclo 3.2.1]oct-2-ene and -octane derivatives |
| 02/18/2004 | EP1133477B1 Substituted benzimidazoles and their use as parp inhibitors |
| 02/18/2004 | EP1028744B1 Neuronal uses of bmp-11 |
| 02/18/2004 | EP0980351B1 Benzylamine and phenylethylamine derivatives, processes for preparing the same and their use as medicaments |
| 02/18/2004 | EP0946166B1 Use of matrix metalloproteinase inhibitors for promoting wound healing |
| 02/18/2004 | EP0862462B1 Combination of a beta-receptor blocker and an opioid |
| 02/18/2004 | EP0839134B1 Benzoyl piperidines/pyrrolidines for enhancing synaptic response |
| 02/18/2004 | EP0759922B1 New antagonist compounds |
| 02/18/2004 | EP0720482B1 Prosaposin and cytokine-derived peptides as therapeutic agents |
| 02/18/2004 | CN1476448A Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents |
| 02/18/2004 | CN1476447A Aminothiazoles and their use as adenosine receptor antagonists |
| 02/18/2004 | CN1476434A Novel compounds |
| 02/18/2004 | CN1476427A Phenoxyphenyl alkane sulfonates |
| 02/18/2004 | CN1476424A 萘衍生物 Naphthalene Derivatives |
| 02/18/2004 | CN1476326A Treatment of PCP addiction and PCP addiction-related behavior |
| 02/18/2004 | CN1475490A Valerian extract and its preparation method and use |
| 02/18/2004 | CN1475488A Fluoro isoflavone containing derivative, monufacturing method and its use |
| 02/18/2004 | CN1475487A Fluoro flavon containing compound, manufacturing method and its use |
| 02/18/2004 | CN1475486A Chiral 3-aryl benzo phthalein kind compound, synthesis method and use |
| 02/18/2004 | CN1475214A Application of amyl ethyl quin ether hydrochloride |
| 02/18/2004 | CN1475209A Slow-released agent form of sertraline |
| 02/18/2004 | CN1475208A Slow-released agent form of sertraline |
| 02/18/2004 | CN1475207A Solid oral dosage mode containing walshaden and hydrochloric thizaine |